Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ: ARDX )

5.420 -0.020 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
From Robbins LLP
Via Business Wire
What 6 Analyst Ratings Have To Say About Ardelyx
Via Benzinga
Analyst Expectations For Ardelyx's Future
Via Benzinga
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
How Is The Market Feeling About Ardelyx?
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
Via Benzinga
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
From Robbins LLP
Via GlobeNewswire
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
Get Your Money Out of These 3 Biotech Stocks Before the End of July
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies. 
Via InvestorPlace
Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment
Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
From Ardelyx, Inc.
Via GlobeNewswire
Why Ardelyx Stock Is Dropping
Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD)... 
Via Benzinga
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
From Ardelyx, Inc.
Via GlobeNewswire
3 Stocks Under $10 With the Potential to Make You a Millionaire
Looking for volume plays? Here are three stocks under $10 that might just drive your earnings to millions in the next few years. 
Via InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
The 3 Best Penny Stocks to Buy in May 2024
Ride the momentum with these affordable penny stocks as they continue to display for solid profits this year. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS